Collegium Pharma (COLL) Stock Price, Quote & News

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-dete...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 713 3699

Website: www.collegiumpharma.com

Address:

100 Technology Center Drive, Suite 300, Stoughton, United States

WilkinsRF Oct. 20 at 9:53 PM

$COLL right near 35 from under 31. With this momentum we could be at new highs from earnings or before

0 · Reply

WilkinsRF Oct. 15 at 9:11 PM

$COLL reversal of flush out in progress. 35 to 40 could come fast

0 · Reply

WilkinsRF Oct. 9 at 4:03 PM

$COLL there is a group selling out but this will be a great buying opportunity. Keep accumulating. Reminds me of $HCI when it dropped below 100. Now it's 190. This is worth 60 easily

0 · Reply

WilkinsRF Oct. 6 at 8:54 PM

$COLL added today on recent weakness. Best adhd product on the market and should experience major multi year growth while enjoying high fcf from pain franchise

1 · Reply

jewell69 Oct. 3 at 6:20 PM

TRYING 2 BY 90 $DKNG 35.10 now b a .21 x .22 moved from Greece $GREK to Chile $ECH TOOK 1.4% PROFIT IN $COLL B YESTERDAY, 10/2 SOLD TODAY 10/3

0 · Reply

jewell69 Oct. 3 at 6:00 PM

$COLL B 10/2 34.30 S TODAY 10/3 34.66

0 · Reply

hawkmdend Oct. 3 at 3:43 PM

$CING I have to add $COLL as a potential buyer/partner. The new Chief Legal Officer, Nilay Patel, comes from Ironshore Pharm, which Collegium acquired to expand its presence in the ADHD/CNS space. This is getting very interesting… my Money is with COLL or $SUPN. I'm done with my DD. Happy trading, nothing else to add.

1 · Reply

jewell69 Oct. 2 at 5:10 PM

$COLL trying 2 by 200 34.30 now 1:04 pm edt b a 34.39 x .42 recent historical trades: 09/19/2025 Sell COLLEGIUM PHARMACEUTICAL 100 $35.8159 $0.02 $3,581.57 09/15/2025 Buy COLLEGIUM PHARMACEUTICAL 100 $34.92 -$3,492.00 09/11/2025 Sell COLLEGIUM PHARMACEUTICAL 100 $38.5246 $0.02 $3,852.44 09/08/2025 Buy COLLEGIUM PHARMACEUTICAL 50 $37.58 -$1,879.00 09/08/2025 Buy COLLEGIUM PHARMACEUTICAL 50 $38.09 -$1,904.50 05/23/2025 Sell COLLEGIUM PHARMACEUTICAL 22 $27.06 $595.32 05/20/2025 Buy COLL GIUM PHARMECEUTICAL 22 $30.11 -$662.42 05/20/2025 Sell

0 · Reply

TalkMarkets Sep. 27 at 3:20 AM

Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI $MASI $COLL Also $ALC $SONVY https://talkmarkets.com/content/stocks--equities/dont-overlook-these-2-highly-ranked-medical-stocks-coll-masi?post=525107

0 · Reply

AnneLee847 Sep. 21 at 5:55 AM

$COLL Cosmetic dermatology play. Testing multi-month support. Volume decline concerning.

0 · Reply

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 22, 2025, 8:00 AM EDT - 2 days ago

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

Oct 13, 2025, 8:00 AM EDT - 11 days ago

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Sep 8, 2025, 5:03 PM EDT - 6 weeks ago

Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Collegium to Participate in Upcoming Investor Conferences

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

Aug 7, 2025, 2:00 PM EDT - 2 months ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 2 months ago

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

Jul 24, 2025, 8:00 AM EDT - 3 months ago

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 8:00 AM EDT - 3 months ago

Collegium Announces $150 Million Share Repurchase Program

Jun 30, 2025, 2:53 PM EDT - 4 months ago

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

May 12, 2025, 8:05 AM EDT - 5 months ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

May 9, 2025, 2:04 AM EDT - 6 months ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 6 months ago

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Apr 24, 2025, 8:00 AM EDT - 6 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 1, 2025, 8:00 AM EDT - 7 months ago

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 7 months ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 7 months ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Mar 10, 2025, 6:57 PM EDT - 8 months ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Mar 9, 2025, 4:07 AM EDT - 8 months ago

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Feb 27, 2025, 9:03 PM EST - 8 months ago

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 8 months ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 8:00 AM EST - 9 months ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Jan 8, 2025, 8:00 AM EST - 10 months ago

Collegium Provides 2025 Financial Guidance and Business Update

Nov 26, 2024, 8:00 AM EST - 11 months ago

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 14, 2024, 4:30 PM EST - 1 year ago

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Nov 8, 2024, 12:30 AM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

Collegium Reports Record Third Quarter 2024 Financial Results

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 9:30 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Collegium Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 6:00 AM EDT - 1 year ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

May 29, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Global Healthcare Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

May 9, 2024, 7:32 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:02 PM EDT - 1 year ago

Collegium Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Mar 12, 2024, 5:00 AM EDT - 1 year ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BLBD GCT PLMR RAMP RDCM

Feb 22, 2024, 9:52 PM EST - 1 year ago

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:09 PM EST - 1 year ago

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Feb 8, 2024, 8:00 AM EST - 1 year ago

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Nov 27, 2023, 8:00 AM EST - 2 years ago

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Nov 7, 2023, 10:15 PM EST - 2 years ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 2 years ago

Collegium Reports Third Quarter 2023 Financial Results

Oct 24, 2023, 2:59 PM EDT - 2 years ago

Collegium Pharmaceutical: Delivering On Promises

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023

Aug 28, 2023, 8:00 AM EDT - 2 years ago

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

Aug 12, 2023, 5:25 AM EDT - 2 years ago

Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates

WilkinsRF Oct. 20 at 9:53 PM

$COLL right near 35 from under 31. With this momentum we could be at new highs from earnings or before

0 · Reply

WilkinsRF Oct. 15 at 9:11 PM

$COLL reversal of flush out in progress. 35 to 40 could come fast

0 · Reply

WilkinsRF Oct. 9 at 4:03 PM

$COLL there is a group selling out but this will be a great buying opportunity. Keep accumulating. Reminds me of $HCI when it dropped below 100. Now it's 190. This is worth 60 easily

0 · Reply

WilkinsRF Oct. 6 at 8:54 PM

$COLL added today on recent weakness. Best adhd product on the market and should experience major multi year growth while enjoying high fcf from pain franchise

1 · Reply

jewell69 Oct. 3 at 6:20 PM

TRYING 2 BY 90 $DKNG 35.10 now b a .21 x .22 moved from Greece $GREK to Chile $ECH TOOK 1.4% PROFIT IN $COLL B YESTERDAY, 10/2 SOLD TODAY 10/3

0 · Reply

jewell69 Oct. 3 at 6:00 PM

$COLL B 10/2 34.30 S TODAY 10/3 34.66

0 · Reply

hawkmdend Oct. 3 at 3:43 PM

1 · Reply

jewell69 Oct. 2 at 5:10 PM

0 · Reply

TalkMarkets Sep. 27 at 3:20 AM

0 · Reply

AnneLee847 Sep. 21 at 5:55 AM

$COLL Cosmetic dermatology play. Testing multi-month support. Volume decline concerning.

0 · Reply

jewell69 Sep. 15 at 7:41 PM

buying both $QURE and $COLL on a mkt on close order today 9/15/25 bad luck, bought $COLL JUST LAST FRIDAY 9/12

0 · Reply

jewell69 Sep. 8 at 7:15 PM

$COLL 2nd buy today throwing good money after bad. Buy 50 Limit $37.58 Day $37.58 $37.90 $37.91 $37.94

0 · Reply

jewell69 Sep. 8 at 2:56 PM

$COLL got opium ? truth be told; pain medicine Settlement date: 09/09/2025 Action: Bought Quantity: 50 Symbol: COLL Unit price: $38.09 Principal amount $1,904.5*

0 · Reply

jewell69 Sep. 6 at 7:39 PM

set it, and forget it ! for Monday, trying to buy 50 $COLL 38.09 rationale: -.6% lower than friday 9/5/25 close

0 · Reply

jewell69 Sep. 6 at 7:34 PM

$COLL modest+ earnings beat 8/7/25; up about a half a ton since then, but -3.04% last 10 trading days; including -2.32% on Friday 9/5 traded out of it for smallish profits Date Jun-06-2025 Shares -500.000 Price $29.85 Amount $14,923.75 friday 9/5 close 38.32 obviously, you would be paying up since 8/7 earnings beat

0 · Reply

Doozio Sep. 6 at 4:03 AM

$COLL it was always 🐒🍌🧠⏰♾️ wen yo wud get tight with the da huckleberries below da $$$$$. Whuts that 🐑 short interest????

0 · Reply

Estimize Aug. 25 at 1:03 PM

Wall St is expecting 1.88 EPS for $COLL Q3 [Reporting 11/06 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co

0 · Reply

MergeMarkets Aug. 23 at 10:01 AM

$COLL Collegium Pharmaceutical Inc is facing opioid litigation concerns and generic competition risks

0 · Reply

stockpicker63 Aug. 15 at 6:04 PM

Nice profits on the free tips van Swingstocktraders. $AUPH now +34%, $PLUG now +16%, $ELAN +5%, $COLL +5.5%, $KOD +18%.

1 · Reply

net0trader Aug. 13 at 6:56 PM

$ANIP $CELC $COLL I am out of all 3 names ..

0 · Reply

net0trader Aug. 13 at 1:56 AM

$ANIP $CELC $COLL these really exceeded my expectations... Quite some momentum

0 · Reply

stockpicker63 Aug. 11 at 1:57 PM

Stocks to watch now! $COLL and $ELAN

0 · Reply

Market Cap	1.12B
Revenue (ttm)	631.45M
Net Income (ttm)	69.19M
EPS (ttm)	N/A
PE Ratio	6.15
Forward PE	5.69
Profit Margin	10.96%
Debt to Equity Ratio	2.52

Volume	181,800
Avg Vol	389,636
Day's Range	N/A - N/A
Shares Out	31.50M
Stochastic %K	82%
Beta	0.65
Analysts	Strong Sell
Price Target	$44.60